2RZ.SG,0P0001KBA8,0 (2RZ.SG)

3.0140

+0.2080

+(7.41%)

As of July 23 at 10:00:00 PM GMT+2. Market Open.

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today will highlight interim clinical data from its Phase 1 trial of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma (RRMM), including new profiling of patient responses from Arm C, an optimized lymphodepletion arm. The P-BCMA-ALLO1 data are being presented, along

PR Newswire 4 months ago

PSTX
Poseida Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Jennifer Kim downgraded Poseida Therapeutics (PSTX) to Neutral from Overweight without a price target after the company entered into a merger agreement to be acquired by Roche (RHHBY) at a price of $9.00 per share in cash at closing, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones. Published first on TheFly – the ultimate source for real-time, mark

TipRanks 5 months ago

PSTX
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

Poseida Therapeutics, Inc. (Nasdaq: PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that it has entered into a merger agreement to be acquired by Roche Holdings, Inc. ("Roche") at a price of $9.00 per share in cash at closing, plus a non-tradeable CVR to receive certain contingent payments of up to an aggregate of $4.00 per share in cash

PR Newswire 5 months ago

PSTX
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced plans to share progress across its clinical- and earlier-stage pipeline of differentiated T stem cell memory cells (TSCM)-rich allogeneic CAR-T therapies in oncology and autoimmune diseases during a virtual R&D Day to be held today at 10:00am ET / 7:00am PT.

PR Newswire 5 months ago

PSTX
Poseida Therapeutics to Present at Two Upcoming Investor Conferences

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that the Company will participate in the following upcoming investor conferences:

PR Newswire 5 months ago

PSTX
Poseida Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Poseida Therapeutics ( NASDAQ:PSTX ) Third Quarter 2024 Results Key Financial Results Revenue: US$71.7m (up by US$62.4m...

Simply Wall St. 5 months ago

PSTX
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced updates and financial results for the third quarter ended September 30, 2024.

PR Newswire 5 months ago

PSTX
Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced new preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM), along with platform enhancements aimed at enhancing potency and improving targeting of solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) 39th An

PR Newswire 5 months ago

PSTX
Organogenesis Holdings And 2 Other US Penny Stocks To Watch

As the U.S. stock market navigates the uncertainty surrounding the presidential election and upcoming Federal Reserve interest rate decisions, investors are keeping a close eye on various sectors for potential opportunities. In this context, penny stocks—typically representing smaller or newer companies—remain an intriguing option for those seeking affordability combined with growth potential. By focusing on companies with strong financials, investors can uncover promising candidates within...

Simply Wall St. 5 months ago

PSTX

ORGO

SEER
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune, and rare diseases, today announced the upcoming presentation of new preclinical data supporting the potential of P-KLKB1-101, a liver-directed genetic medicine that uses the Company's Cas-CLOVER™ Site-Specific Gene Editing System, for the treatment of patients with hereditary angioedema (HAE). The dat

PR Newswire 6 months ago

PSTX
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune, and rare diseases, today announced the nomination of a new development candidate under its collaboration with Roche. The nomination triggered a $15 million milestone payment from Roche to Poseida.

PR Newswire 6 months ago

PSTX
MaxCyte Appoints Cynthia Collins to its Board of Directors

ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company’s Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board’s

GlobeNewswire 6 months ago

CERT

DMTKQ

MXCT
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced its inclusion in Newsweek Magazine's annual America's Top Most Loved Workplaces® list, developed by Most Loved Workplace®, a division of Best Practice Institute (BPI).

PR Newswire 6 months ago

PSTX
$Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients$

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced new interim clinical data from its ongoing Phase 1 trial of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma (RRMM). Data1 demonstrated a 91% overall response rate (ORR) and compelling safety results in the 23 heavily pretreated patients in Arm C, an optimized l

PR Newswire 6 months ago

PSTX
$Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma$

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to P-BCMA-ALLO1, an investigational stem cell memory T cell (TSCM)-based allogeneic CAR-T cell therapy in Phase 1/1b clinical development for the treatment of patien

PR Newswire 7 months ago

PSTX
$Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting$

Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, announced today that new clinical data from an ongoing Phase 1 study of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma will be presented in an oral session at the 21st International Myeloma Society (IMS) Annual Meeting, which is being held in Rio de Janeiro from September 25-

PR Newswire 7 months ago

PSTX
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, highlighted new data from a case study of a patient with relapsed multiple myeloma treated in a clinical trial of P-BCMA-101, the Company's original investigational T stem cell memory (TSCM)-rich BCMA targeting autologous CAR-T cell therapy. The data were presented in an oral session at the Soci

PR Newswire 7 months ago

PSTX
Poseida Therapeutics to Present at Upcoming Investor Conferences

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the Company will participate in fireside chats at the following upcoming investor conferences in September:

PR Newswire 7 months ago

PSTX
Poseida Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Poseida Therapeutics ( NASDAQ:PSTX ) Second Quarter 2024 Results Key Financial Results Revenue: US$26.0m (up 30% from...

Simply Wall St. 8 months ago

PSTX
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced updates and financial results for the second quarter ended June 30, 2024.

PR Newswire 8 months ago

PSTX

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Breaking

2RZ.SG,0P0001KBA8,0 (2RZ.SG)

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting

Poseida Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

Poseida Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024

Organogenesis Holdings And 2 Other US Penny Stocks To Watch

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche

MaxCyte Appoints Cynthia Collins to its Board of Directors

Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma

Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma

Poseida Therapeutics to Present at Upcoming Investor Conferences

Poseida Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024